In summary, we have identified and validated C/EBPα activation as the key PR mechanism for FLT3i in FLT3-ITD AML and further determined that combining existing drugs targeting C/EBPα and its regulated gene network with FLT3i can overcome PR and enhance the efficacy of FLT3i. The gene discussed is CEBPA; the disease is acute myeloid leukemia.